

Scientist Profile

Name: Srikanth Tripathy
Designation: Scientist G
Date of Birth: 13/06/1958
Date of Joining: 5/7/1986
Date of joining present post: 7/12/2015
Discipline: HIV Laboratory HIV, TB
Address (off.) including Contact Number* : Dr Srikanth Tripathy
No.1 Mayor Sathyamoorthy Road
Chetput, Chennai-600031
Contact Number*: 044-28369600 91-9500779797
Email address*: directornirt@nirt.res.in; srikanth.p@nirt.res.in

*** Mandatory**

Educational Qualifications (*begin with descending order*)

DEGREE	INSTITUTION AND LOCATION	YEAR (S)	FIELD OF STUDY
M.D.	Madras Medical College, Chennai	1987	Medicine
M.B.B.S.	Madras Medical College, Chennai	1982	Medicine

1. Research Experience:

Sl.NO.	Period		Designation	Institute
	From	To		
1	April	June 1986	Assistant Research Officer in Filariasis project	Tuberculosis Research Centre, Madras, India
2	July 1986	April 1988	Research Officer	Tuberculosis Research Centre, Madras, India
3	April 1988	Oct 1990	Research Officer	ICMR-AIIMS AIDS Referral Centre, New Delhi, India
4	Oct 1990	July 1991	Research Officer	AIDS Unit, National Institute of Virology, Pune, India.
5	July 1991	Sept 1992	Senior Research Officer	National AIDS Research Institute, Pune
6	Sept 1992	July 1996:	Senior Research Officer	National AIDS Research Institute, Pune
7	July 1996	July 2001	Assistant Director	National AIDS Research Institute, Pune
8	July 2001	July 2006	Deputy Director	National AIDS Research Institute, Pune
9	July 2006	Sep 2011	Scientist F, Deputy Director (SG),	National AIDS Research Institute, Pune
10	Sep 2011	Jan 2013	Scientist G	National AIDS Research Institute, Pune
11	Feb 2013	Nov 2015	Director	National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra
12	Dec 2015	Present	Scientist G	National Institute for Research in Tuberculosis, Chennai

2. Membership/Fellowship of Professional Societies/Associations :

Membership of National and International Bodies:-

National:

1. Life Member, Indian Chest Society (ICS)

International:

1. Member of the International AIDS Society
2. Member of the International Association of Physicians in AIDS Care (IAPAC)

3. **Workshops/Conferences/Symposiums:**

1. **Tripathy S**, Chaudhuri K, Singh YN, Seth P, Varghese T and Malaviya AN. (1989) HIV screening of commercially available blood products in India. Poster presented at the Vth International Conference on AIDS at Montreal, Canada, June 4-9.
2. Bhargva A, Singh YN, Kumar A, **Tripathy S**, Malaviya AN. (1990) Difficulties in the nursing care of HIV positive patients in India. VIth International Conference on AIDS at San Francisco June 20-24.
3. **Tripathy S**, Cindy K, Charasche P, Chaisson R and Quinn TC. (1991) Mycobacterial infection in HIV-1 seropositive and seronegative individuals at the Johns Hopkins Hospital, Baltimore. VIIth International Conference on AIDS at Florence, June 16-20.
4. **Tripathy SP**, Bannerjee K, Rodrigues JJ, Deshpande SG, Tripathy S. (1993) HIV-2 seroprevalence in STD clinic patients at Pune. IXth International Conference on AIDS at Berlin June 6-11.
5. **Tripathy S**, Renjifo B, McFarlane MF, Tripathy SP, Essex M. V3 region sequences from HIV-1 isolates from India.(1994) V3 region sequences from HIV-1 isolates from India. Xth International Conference on AIDS at Yokohama, Japan July.
6. **Tripathy S**. (1997) Clinical presentation and management of HIV/TB. International Conference on AIDS India 2000 at Chennai Nov 27th to Dec 1st, 2000.
7. **Tripathy S**, Joshi DR, Paranjape RS, Menon P, Patil U, Gadkari DA.(1998) Sentinel surveillance for HIV infection in tuberculosis patients in Pune, India. XIIth International Conference on AIDS at Geneva June 28th - July 3.
8. National Conference on HIV /AIDS: Prevention and Care: Key to success : from 17th to 19th January 2003, Renaissance Hotel, Mumbai organized by Yuvak Prathisthan in association with NACO-IAVI-WHO-ARCONUNAIDS-MSACS-AVERT-SOCIETY-MDACS and gave an oral presentation on “Epidemiology of HIV associated tuberculosis”
9. Attended the Asia Regional Training in HIV/AIDS Clinical Care in Preparation for HPTN 052 and AACTG 5175 held at Le Meridian Hotel from 10th to 14th March 2003 at Chennai, India.
10. Attended the Adult AIDS Clinical Trials Group Leadership Retreat, held from December 10-13, 2003, at the Baltimore Marriott Waterfront, Baltimore, Maryland, USA
11. National CME on HIV and tuberculosis at the Russian Cultural Centre, Kasturi Ranga Road, Alwarpet, Chennai (organized by the Tuberculosis Research Centre, ICMR, Chennai and the National Academy of Medical Sciences, New Delhi) on 11/9/04 and gave an oral presentation on “Overview of Preventive Therapy Trials”
12. “Third Workshop of the National Task Force for the Involvement of Medical Colleges in the RNTCP” held at AIIMS from the 23rd to 24th November 2004 and took part in the discussions in the group meetings
13. ACTG 5175 related training organized by Miriam Hospital, Brown University at Providence, USA from 23rd to 27th March 2004.
14. Adult AIDS Clinical Trials Group Leadership Retreat: Winter Meeting at San Diego, USA from March 24th to 28th 2004.

15. Attended the ACTG Summer meeting at Arlington, USA from July 31st 2004 to August 4th 2004.
16. Adult AIDS Clinical Trials Group (AATCG) Winter Meeting which was being held between December 3rd to December 7th 2004, at Baltimore, Maryland, USA.
17. National Conference on HIV/AIDS in India held at Delhi from the 2nd to 4th April 2005 and presented a paper on “HIV subtyping in India and its implications”.
18. Symposium on Anti-retroviral Therapy organized in Pune on the 5th of April 2005 and did a presentation on “Opportunistic Infection related issues in the Indian Setting”
19. INSAFCON 2005 meeting organized by the Rajasthan State AIDS Society from the 16th to 17th April 2005 at Jaipur and presented a paper on “HIV Subtyping in India”.
20. Grant Writing Training organized at Bangkok, Thailand from 20th – 21st April 2005 related to the “CTU RFA Pre-Application Meeting organized by the National Institutes of Health, USA.
21. National Consultation on Drug Resistance in Malaria, TB & HIV/AIDS from the 19th to 21st September 2005 at Mumbai and gave oral presentations on (1) Clinical aspects of anti HIV drug resistance and (2) HIV TB co- infection treatment in India.
22. United States - Japan Cooperative Medical Sciences Program (CMSP) 10th International Conference on Emerging Infectious Diseases in the Pacific Rim from November 16-17, 2005 at Hanoi in Vietnam.
23. AIDS Clinical Trials Group Meeting, Baltimore Marriott Waterfront Hotel — Baltimore, Maryland, USA from November 29 – December 2, 2005.
24. VIIth Sir Dorabji Tata Symposium held at JRD Tata Auditorium, National Institute of Advanced Studies (NIAS), Indian Institute of Science Campus, Bangalore 560012 from 10th – 11th March 2006 and gave an oral presentation on “Clinical Monitoring of HIV seropositive individuals for disease progression”.
25. Attended the Workshop conducted by DBT / ICMR / DCGI and US-DHHS on “Clinical Trials and Clinical Research” at Mumbai from April 4 – 6, 2006.
26. Attended the National Conference on HIV and AIDS from 21st to 23rd April 2006 and gave a talk on Epidemiology of HIV/TB and arranged the symposium on HIV/TB on the 21st of April 2006 at New Delhi.
27. ACTG Winter Meeting from 4th to 7th December 2007 at Baltimore, Maryland, USA.
28. DFID meeting at London, UK from 10th to 14th December 2007.
29. Adult AIDS Clinical Trials Group (AATCG) Leadership Retreat Meeting which is held between 3rd to 6th March 2008 at Denver, USA.
30. **Tripathy S**, Garg R, Srikantiah P, Jadhav S, Haldar P, Hingankar N, Chaturbhuj D, Mathur M, Mehta P, Reddy DCS, Kabra S, Paranjape RS. Absence of transmitted HIV drug resistance in Threshold Survey among voluntary counseling and testing clients in Mumbai, India. Poster presented at the XVIIth International Conference on AIDS held at Mexico in 2008.
31. Adult AIDS Clinical Trials Group (AATCG) Leadership Retreat which was held between December 4th – 7, 2008 at Baltimore, USA.

32. Bi-regional Workshop on Prevention and Surveillance of HIV Drug Resistance held at Bangkok, Thailand from 20th to 22nd May 2009.
33. AIDS Clinical Trials Group Network Meeting held at Washington June 24th – 28th, 2009.
34. AIDS Clinical Trials Group Meeting held at Washington DC from June 17th – 21st, 2010.
35. Arranged a Workshop on “HIV Drug Resistance Testing” from 19-20 March 2010. This was an EFA Sponsored Workshop held at NARI in Pune and gave a presentation on National HIV-1 Drug Resistance Scenario.
36. Took part in the Pre-Conference Continuing Education Workshop arranged by NACO at the India Habitat Centre and gave a talk on “Clinical Trials” on 18th Jan 2011 in New Delhi.
37. Attended the National Conference on HIV/AIDS Research organized by NACO at the India Habitat Centre, New Delhi and gave two talks on “Response to treatment with Nevirapine based versus Efavirenz based antiretroviral therapy regimens in ART naïve HIV infected patients with active Tuberculosis in Pune, India” and “Generation of HIV-1 subtype C base DNA vaccine candidates assessment of prime boost immunization strategy in mouse model” on the 19th and 20th Jan 2011.
38. Attended the meeting organized at NARI, Pune 26-28th Jan 2011 on “Galvanizing Evidence for HIV Management” and gave a talk on “HIV/TB Research in India”.
39. Attended the “International Conference on Emerging Frontiers and Challenges in HIV/AIDS Research” organized by NIRRH at Mumbai from, February 5 to 8, 2011 and gave a presentation on “Clinical response of newly diagnosed HIV seropositive and seronegative pulmonary tuberculosis patients with the RNTCP regimen in Pune, India”.
40. Attended the AIDS Clinical Trials Group Meeting held at Atlanta USA from November 18 – 20, 2010 and took part in the meeting.
41. Attended the AIDS Clinical Trials Group Meeting held at Washington DC USA from June 21 – 24 , 2011.
42. Attended the AIDS Clinical Trials Group (ACTG) Scientific Retreat and the CROI meeting held between March 4-10, 2012, in Seattle Washington, USA.
43. Attended the AIDS Clinical Trials Group (ACTG) Meeting held between 16 to 20 July, 2012 at Washington DC, USA and took part in the deliberations of the meeting.
44. AIDS Clinical Trials Group (ACTG) Meeting, 7th to 8th March, 2013, Atlanta, USA.
45. 29th Biennial Indian Association of Leprologists (IAL) Conference 2014 28th to 30th March 2014, PGI, Chandigarh.
46. Meeting of National Leprosy Programme Managers Kuta, Bali, Indonesia from 23rd Sept 2014 to 25th Sept 2014 and gave a talk on “Relapse and MDT Resistance in Leprosy”.
47. Ranbaxy Science Foundation 33rd Round Table Conference: Strategies for Elimination/Eradiation of Leprosy on 4th Feb 2015 and gave a talk on “Epidemiology of Leprosy”.
48. Zonal Task Force Workshop 2014 (North Zone India) organized by the Central TB Division, Government of India, State TB Cell organized by STF & Government Medical College and Hospital , Chandigarh Feb 13-14, 2015.

49. Attended the CME on leprosy conducted by IAL and gave a talk on Epidemiology of Leprosy at *S C B* Medical College, Cuttack (Odisha) on 08th May, 2015.
 50. Attended the CME on leprosy conducted by IAL and gave a talk on Epidemiology of Leprosy at Raja Muthiah Institute of Medical Sciences, Chidambaram, Tamil Nadu on 19th June, 2015.
 51. Attended the CME on leprosy conducted by IAL and gave a talk on Epidemiology of Leprosy at CMC, Ludhiana on 25th July 2015
 52. Abstract titled, "HIV DRUG RESISTANCE WITH EARLY VS DELAYED ANTIRETROVIRAL TREATMENT (HPTN 052)" (ID 184), has been accepted for poster presentation at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI), which will be held during 4 - 7 March, 2018 in Boston, Massachusetts.
- .
4. Awards : Fogarty Fellow at the Harvard School of Public Health, 1992 – 1994.
 5. Miscellaneous: Nil
 6. **Publications:**
 1. Dissertation on "Abdominal Tuberculosis- clinical aspects" submitted by **Tripathy S** to the Madras University in 1985 as part of MD thesis.
 2. **Tripathy S**, Malaviya AN, Singh YN, Chaudhuri K, Varghese T. HIV screening of commercially available blood products in India. *Indian J Med Res* 1991;93:15-18.
 3. **Tripathy S**, Kumar A, Manivel V, Panda SK and Rao KVS. Design and synthesis of a self assembling peptide derived from the envelope proteins of Human Immunodeficiency virus type 1: an approach to heterovalent immunogens. *J. of Immunology* 1992;148:4012-4020.
 4. **Tripathy S**. HIV-1 isolates from India. *Bulletin of the Centre for AIDS Research and Control (CARC Calling)*. Mar 1995.
 5. **Tripathy S**, Renjifo B, Wang W-K, Mclane MF, Bollinger R, Rodrigues J, Osterman J, Tripathy SP, Essex M. gp120 sequences of Primary HIV-1 isolates from Pune and New Delhi in India. *AIDS Res and Hum Retr (ARHR)* 1996;12(12):1203-1206.
 6. **Tripathy S**, Menon P, Joshi DR, Patil U, Gadkari DA and Paranjape RS. Preliminary observations on lymphocyte subpopulations in HIV seropositive and HIV seronegative tuberculosis patients in Pune, India. *Indian J Med Res* 2000;111:195-198.
 7. **Tripathy S**, Joshi DR, Mehendale SM, Menon P, Joshi AN, Ghorpade SV, Patil U, Paranjape RS. Sentinel surveillance for HIV infection in tuberculosis patients in India. *Ind J Tub* 2002;49:17-20.

8. **Tripathy S**, SD, Agnihotri KD, Basu S, Kulkarni SS, Jere AJ, Kurle S, Bhattacharya SK, Singh K, Tripathy SP and Ramesh S. Paranjape. Detection of Subtype C and Subtype B HIV-1 Recombinants North-eastern state of Manipur in India. ARHR 2005;21:152-7.
9. **Tripathy S**, Anand A, Inamdar V, Manoj MM, Khillare KM, Datye AS, Iyer R, Kanoj DM, Thakar M, Kale V, Pereira M, Risbud AR. Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India. Indian J Med Res. 2011 May;133:521-8.
10. Chaturbuj DN, Hingankar NK, Srikantiah P, Garg R, Kabra S, Deshmukh PS, Jadhav SD, Thorat SR, Datkar SR, Mehta P, Ingole N, Mathur M, Ramachandran A, Bachani D, Rao S, **Tripathy SP** and Paranjape RS. Transmitted HIV Drug Resistance among Newly Diagnosed Drug-naïve HIV-1-infected clients attending Voluntary Counseling and Testing Centres (VCTC) in Mumbai, India. AIDS Research and Human Retroviruses 2010;26:927-932. Impact factor 2.246, Citations 17.
11. Smita R. Thorat, Devidas N. Chaturbuj, Nitin K. Hingankar, Velura Chandrasekhar, Rajasekhar Koppada, Sharda R. Datkar, Padmini Srikantiah, Renu Garg, Sandhya Kabra, Partha Haldar, Dandu C.S. Reddy, Damodar Bachani, **Srikanth P. Tripathy** and Ramesh S. Paranjape. Surveillance of Transmitted HIV Type 1 Drug Resistance Among HIV Type 1-Positive Women Attending an Antenatal Clinic in Kakinada, India. AIDS Research and Human Retroviruses. December 2011, 27(12): 1291-1297. doi:10.1089/aid.2011.0036. Impact factor 2.246. Citations 14.
12. Nitin K Hingankar, Smita R. Thorat, Alaka Deshpande, S Rajasekaran, C Chandrasekar, Suria Kumar, Padmini Srikantiah, Devidas N Chaturbuj, Sharda R. Datkar, Pravin S Deshmukh, Smita Kulkarni, Suvarna Sane, DCS Reedy, Renu Garg, Michael R. Jordan, Sandhya Kabra, **Srikanth P Tripathy** and Ramesh S Paranjape. Initial virologic response and HIV drug resistance among HIV-1 infected individuals initiating first line antiretroviral therapy at two clinics in Chennai and Mumbai India. Clinical Infectious Diseases (CID 2012;54 (Suppl 4):S348-53. **Impact factor 9.154. Citations 16.**

9.2 Publication as Co-author:

1. Malaviya AN, Seth P, Singh RR, **Tripathy S**. AIDS and HIV screening in Northern India. The National Medical Journal of India. 1989;2(1):22-25.
2. Malaviya AN, **Tripathy S**, Singh YN, Chaudhuri K, Ashok Kumar. Clinical approaches to AIDS and HIV infection. Bulletin of the Centre for AIDS Research & Control (CARC Calling). 1989;2(2,3,4) 25-28.
3. Malaviya AN, **Tripathy S**, Singh YN, Chaudhuri K, Ashok Kumar. A set up for the management of patients infected with HIV. Bulletin for the Centre for AIDS Research & Control (CARC Calling) 1989;2(2,3,4) 25-28.
4. Malaviya AN, **Tripathy S**, Chaudhuri K, Singh YN, Seth P. The anti-D vaccine episode: lessons for everyone in the HIV field. Bulletin of the Centre for AIDS Research & Control (CARC Calling) 1989;2(1):12-14.
5. Malaviya AN, **Tripathy S**, Singh YN, Chaudhuri K, Seth P, Varghese T. Anti D Vaccine and HIV. Nat Med J India 1989;2(2):96.
6. Malaviya AN, Chaudhuri K, Singh YN, **Tripathy S**, Kumar A. The clinical management of AIDS. Bulletin of the Centre for AIDS Research & Control (CARC Calling) 1989;2(5):22-25.
7. Singh YN, Malaviya AN, **Tripathy S**, Chaudhuri K, Bhargava NC, Khare SD. HIV serosurveillance among prostitutes and patients from a Sexually Transmitted Diseases Clinic in Delhi, India. J. of Acquired Immune Deficiency Syndrome 1990;3:287-289.
8. Singh YN, Malaviya AN, **Tripathy S**, Chaudhuri K, Khare SD, Nanu A, Bhasin R. Human Immunodeficiency Virus infection in blood donors of Delhi, India. J Acquir Imm Defic Synd 1990;3:152-154.
9. Singh YN, Bhargava M, Malaviya AN, **Tripathy S**, Kakkar A and Khare SD. Human Immunodeficiency virus infection in Asian Indian patients with haemophilia and those who had multiple transfusions. Indian J Med Res 1991; 93:12-14.
10. Selvakumar N, Reetha AM, Vanaja Kumar, **Tripathy SP**, Narayana ASL, Sivasubramanian S, Paramasivan CN and Prabhakar R. Mycobacteriuria in pulmonary tuberculosis patients in Madras, South India. Ind J Tub 1994;41:43-45.
11. Joshi DR, Toshniwal R, **Tripathy SP**, Menon PA, Khatavkar P, Paranjape RS, Mehendale SM, Gadkari DA. Clinical and radiological presentation of tuberculosis in HIV

seropositive and HIV seronegative patients in Pune. Proceedings of First National Conference on HIV/AIDS Medicine, Pune 23-24th Nov 1996 pg 35-39.

12. Soto L, **Tripathy S**, Renjifo B, Mclane MF, Essex M. HIV-1 Pol sequences from India diverge from known subtypes. *Jour Acquir Imm Defic Synd* 1996;13:299-307.
13. Balasubramanian R, Nagarajan M, Balambal R, **Tripathy SP**, Sundararam R, Venkatesan P, Paramasivan CN, Rajasambandam P, Rangabashyam N, Prabhakar R. Randomised controlled clinical trial of short course chemotherapy in abdominal tuberculosis: a five year report. *Int J Tuberc Lung Dis* 1997;1(1):44-51. IF 1.233, Citations 41. PMID:9441058
14. Paranjape RS, **Tripathy SP**, Menon PA, Mehendale SM, Khatavkar P, Joshi DR, Patil U, Gadkari DA, Rodrigues JJ. Increasing trend of HIV seroprevalence among pulmonary tuberculosis patients in Pune, India. *Indian J Med Res.* 1997;106:207-11. PMID:9378525
15. Kulkarni SS, **Tripathy S**, Paranjape RS, Mani NS, Joshi DR, Patil U, Gadkari DA. Isolation and preliminary characterization of two HIV-2 strains from Pune, India. *Indian J Med Res* 1999;109:123-130.
16. Cecilia D, Kulkarni SS, **Tripathy SP**, Gangakhedkar RR, Paranjape RS, Gadkari DA. Absence of coreceptor switch with Disease progression in Human Immunodeficiency Virus infection in India. *Virology* 2000;271:253-258. PMID:10860879
17. Choudhury S, Montano MA, Womack C, Blackard JT, Maniar JK, Saple DG, **Tripathy S**, Sahni S, Shah S, Babu GP, Essex M. Increased promoter diversity reveals a complex phylogeny of human immunodeficiency virus type 1 subtype C in India. *J Hum Virol.* 2000;3(1):35-43.
18. Narain JP, Pontali E, **Tripathy S**. Epidemiology and control strategies. *Ind J Tub* 2002;49:3-9.
19. Thakar MR, Patke D, Lakhashe SK, Bhonge L, Kulkarni SV, **Tripathy SP**, Gupte N, Brookmeyer R, Quinn TC, Paranjape RS, Bollinger RC. Consistent subtype-specific anti-HIV type 1 T lymphocyte responses in Indian subjects recently infected with HIV type -1. *AIDS Res Hum Retroviruses.* 2002 Dec 10;18(18):1389-93. PMID:12487810
20. Bhore AV, Sastry J, Patke D, Gupte N, Bulakh PM, Lele S, Karmarkar A, Bharucha KE, Shrotri A, Pisal H, Suryawanshi N, **Tripathy S**, Risbud AR, Paranjape RS, Shankar AV, Kshirsagar A, Phadke MA, Joshi PL, Brookmeyer RS, Bollinger RC Jr. Sensitivity and specificity of rapid HIV testing of pregnant women in India. *Int J STD AIDS.* 2003 Jan;14(1):37-41.

21. Risbud A, Pereira M, Meherdale S, Gangakhedkar R, Ghate M, Joshi S, **Tripathy S**. Lack of evidence for sexual transmission of hepatitis C virus in patients attending STD clinics in Pune, India. *Sex Transm Infect.* 2003;79(5):425.
22. Jere A, **Tripathy S**, Agnihotri K, Jadhav S, Paranjape R. Genetic analysis of Indian HIV1 nef: Subtyping, variability and implication. *Microbes and Infection* 2004;6:279-89.
23. Agnihotri K, **Tripathy S**, Jere A, Jadhav S, Kurle S and Paranjape R. gp120 sequences from HIV -1 subtype C early seroconverters in India *AIDS Res Hum Retroviruses.* 2004;20:889-894.
24. Kurle S, **Tripathy S**, Jadhav S, Agnihotri K, Paranjape RS. Full length gag sequences of HIV-1 subtype C recent seroconvertors from Pune, India. *AIDS Res Hum Retroviruses.* 2004;20:1113-1118.
25. Jere A, Piroozmand A, **Tripathy S**, Paranjape R, Sakurai A, Fujita M, Adachi A. Generation and characterization of HIV-1 clones chimeric for subtypes B and C nef. *Int J Mol Med* 2004;14:1087-90.
26. Eshleman SH, Hudelson SE, Gupta A, Bollinger R, Divekar AD, Gangakhedkar RR, Kulkarni SS, Thakar MR, Paranjape RS, **Tripathy S**. Limited evolution in the HIV type 1 Pol region among acute seroconverters in Pune, India. *AIDS Res Hum Retroviruses.* 2005 Jan;21(1):93-7.
27. Kulkarni S, **Tripathy S**, Agnihotri K, Jatkar N, Jadhav S, Umakanth W, Dhande K, Tondare P, Gangakhedkar R, Paranjape RS. Indian primary HIV-2 isolates and relationship between V3 genotype, biological phenotype and co-receptor usage. *Virology* 2005;337:68-75.
28. Joshi SN, Gopalkrishna V, Kishore Kumar B, Dutta S, Nyaynirgune P, Thakar M, **Tripathy S**, Mehendale S, Paranjape R. Cervical Squamous Intra-Epithelial Changes and Human Papillomavirus Infection in Women Infected With Human Immunodeficiency Virus in Pune, India. *J of Med Virology* 2005;76:470-5
29. Bal AM, Lakashe SK, Thakar MR, **Tripathy SP**, Paranjape RS. Dysregulation of proinflammatory and regulatory cytokines in HIV infected persons with active tuberculosis. *Cytokine.*2005;30:275-81. PMID:15927853.
30. **Tripathy SP**, Kulkarni SS, Jadhav SD, Agnihotri KD, Jere AJ, Kurle SN, Bhattacharya SK, Singh K, Tripathy SP, Paranjape RS. Subtype B and subtype C HIV type 1 recombinants in the northeastern state of Manipur, India. *AIDS Res Hum Retroviruses.* 2005 Feb;21(2):152-7. PMID:15725754

31. Pereira M, **Tripathy S**, Inamdar V, Bhavsar M, Date A, Iyer R, Acchammachary A, Mehendale S, Risbud A. Drug resistant pattern of Mycobacterium tuberculosis in seropositive and seronegative HIV-TB patients in Pune, India. *Ind J Med Res* 2005;21:235-9.
32. Ghate MV, **Tripathy SP**, Kumar BK, Godbole SV, Chittake A, Nyayanirgune P, Gangakhedkar RR, Divekar AD, Thakar MR, Risbud AR, Bollinger RC, Mehendale SM. Rate of hospitalization and inpatient care costs for HIV-1-infected patients in Pune, India. *Natl Med J India* 2006;19(1):10-4. PMID:16570678
33. Agnihotri KD, **Tripathy SP**, Jere AP, Kale SM, Paranjape RS. Molecular analysis of gp41 sequences of HIV type 1 subtype C from India. *J Acquir Immune Defic Syndr* 2006;41:345-51. PMID:16540936
34. Sen S, **Tripathy SP**, Paranjape RS. Antiretroviral drug resistance testing. *J Postgrad Med* 2006;52(3):187-193. PMID:16855319
35. Ghate MV, **Tripathy SP**. HIV and gastric disease. *Physician's Digest*. 2006;15(3):25-32.
36. Sen S, **Tripathy SP**, Chimanpure VM, Patil AA, Bhandarkar MS, Umakanth W, Bagul RD, Paranjape RS. Drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment naïve and treatment experienced patients from Pune, India. *AIDS Res Hum Retroviruses* 2007;23(4):489-497. PMID:17506605
37. Kurle SN, Gangakhedkar RR, Sen S, Hayatnagarkar S, **Tripathy S**, Paranjape RS. Emergence of NNRTI Drug Resistance mutations after single dose nevirapine exposure in HIV Type 1 subtype C infected infants in India. *AIDS Res Hum Retrovirus* 2007;23:682-85. PMID:17530993
38. Sen S, **Tripathy SP**, Patil AA, Chimanpure VM and Paranjape RS. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. *AIDS Res Hum Retrovirus* 2007; 23(10):1303–1308. PMID:17961120
39. Gupta A, Gupte N, Sastry J, Bharucha KE, Bhosale R, Kulkarni P, **Tripathy S**, Nayak U, Phadke M, Bollinger RC; BJMCJHU MIT Study Team. Mother to child transmission of HIV among women who chose not to exclusively breastfeed their infants in Pune, India. *Indian J Med Res* 2007 Aug;126(2):131-4.
40. Lakhashe S, **Tripathy S**, Paranjape RS, Bhattacharya J. Characterization of B/C recombinants of near full-length HIV type 1 from northeastern India with mosaics

identical to ARE195FL but with a different ancestral origin. *AIDS Res Hum Retrovirus* 2008;24(1): 92-9.

41. Lakhashe S, **Tripathy S**, Paranjape RS and Bhattacharya J. Evidence of a novel B/C recombinant exhibiting unique breakpoints of near full-length HIV type 1 genome from Northeastern India. *AIDS Res Hum Retroviruses* 2008;24(2): 22934.
42. Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV, Bhosale R, Varadhrajan V, Gupte N, Sastry J, Suryavanshi N, **Tripathy S**, Mmiro F, Mubiru M, Onyango C, Taylor A, Musoke P, Nakabiito C, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwierski S. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. *Lancet*. 2008;372(9635):30013.
43. Kulkarni S, **Tripathy S**, Gangakhedkar R, Jadhav S, Agnihotri K, Sane S, Bollinger R, Paranjape R. Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India. *AIDS Res Hum Retroviruses*. 2008;24(9):115966.
44. Lakashe S, Thakar M, Godbole S, **Tripathy S**, Paranjape R. HIV infection in India: epidemiology, molecular epidemiology and pathogenesis. *J Biosci* 2008;33(4):515-25.
45. Jadhav S, **Tripathy S**, Kulkarni S, Agnihotri K, Risbud A, Paranjape R. Molecular phylogenetics of nearly full length HIV type 2 envelope gene from West India. *AIDS Res Hum Retroviruses*. 2009 Jan;25(1):115-21
46. Ghate M , Deshpande S, **Tripathy S**, Nene M, Gedam P, Godbole S, Thakar M, Risbud A, Bollinger R, Mehendale S. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. *Int J Infect Dis* 2009 Jan;13(1): e1—8.
47. Lall M, Gupta RM, Sen S, Kapila K, **Tripathy SP**, Paranjape RS. Profile of primary resistance in HIV-1 infected treatment naïve individuals from Western India. *AIDS Res Hum Retroviruses* 2008;24(7):987-90. PMID:18593351
48. Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV, Bhosale R, Varadhrajan V, Gupte N, Sastry J, Suryavanshi N, **Tripathy S**, Mmiro F, Mubiru M, Onyango C, Taylor A, Musoke P, Nakabiito C, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwierski S. Extended-

dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India and Uganda; an analysis of three randomized controlled trials. *Lancet*. 2008 Jul 26;372(9635):300-13.

49. Rodriguez MA, Ding M, Ratner D, Chen Y, **Tripathy SP**, Kulkarni SS, Chatterjee R, Tarwater PM, Gupta P. High replication fitness and transmission efficiency of HIV-1 subtype C from India: implications for subtype C predominance. *Virology* 2009; 385(2):416-24. PMID:19157481
50. Sen S, **Tripathy SP**, Sahni AK, Gupta RM, Kapila K, Chopra GS, Chimanpure VM, Patil AA, Paranjape RS. Human immunodeficiency virus type 1 gp 41 mutations in proviral DNA among antiretroviral treatment-naïve individuals from India. *AIDS Res Hum Retroviruses* 2009 May;25(5):521-3. PMID:19400735
51. Jadhav S, **Tripathy S**, Kulkarni S, Agnihotri K, Risbud A and Paranjape R. Molecular Phylogenetics of Nearly Full-Length HIV Type 2 envelope gene sequences from West India. *AIDS Research and Human Retroviruses* 2009;25:115-121.
52. Moorthy A, Gupta A, Bhosale R, **Tripathy S**, Sastry J, Kulkarni S, Thakar M, Bharadwaj R, Kagal A, Bhore AV, Patil S, Kulkarni V, Venkataramani V, Balasubramaniam U, Suryavanshi N, Ziemniak C, Gupte N, Bollinger R, Persaud D for the India SWEN Study Team. Nevirapine Resistance and Breast-Milk HIV Transmission: Effects of Single and Extended-Dose Nevirapine Prophylaxis in Subtype C HIV-Infected Infants. *PLoS ONE* 2009;4(1):e4096.
53. Gupta A, Saple DA, Nadkarni G, Shah B, Vaidya S, Hingankar N, Chaturbhuj D, Deshmukh P, Walshe L, Hudelson SE, James M, Paranjape RS, Eshleman SH, **Tripathy S**. One-, Two-, and Three-Class Resistance among HIV-Infected Patients on Antiretroviral Therapy in Private Care Clinics: Mumbai, India. *AIDS Research and Human Retroviruses*, 2010; 26:25-31.
54. Chaturbhuj DN, Hingankar NK, Srikantiah P, Garg R, Kabra S, Deshmukh PS, Jadhav SD, Thorat SR, Datkar SR, Mehta P, Ingole N, Mathur M, Ramachandran A, Haldar P, Reddy DC, Bachani D, Rao S, **Tripathy SP**, Paranjape RS. Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India. *AIDS Res Hum Retroviruses*. 2010 Aug;26(8):927-32.PMID:20704495
55. Gupta A, Bhosale R, Kinikar A, Gupte N, Bharadwaj R, Kagal A, Joshi S, Khandekar M, Karmarkar A, Kulkarni V, Sastry J, Mave V, Suryavanshi N, Thakar M, Kulkarni S, **Tripathy S**, Sambarey P, Patil S, Paranjape R, Bollinger RC, Jamkar A, and for the Six Week Extended-Dose Nevirapine (SWEN) India Study Team. Maternal Tuberculosis: A Risk Factor for HIV Mother-to-Child Transmission. *JID* 2011;203:358-363.

56. Singh HK, Gupte N, Kinikar A, Bharadwaj R, Sastry J, Suryavanshi N, Nayak U, **Tripathy S**, Paranjape R, Jamkar A, Bollinger RC, Gupta A and for the SWEN India Study Team. High Rates of All-cause and Gastroenteritis related Hospitalization Morbidity and Mortality among HIV-exposed Indian Infants. *BMC Infectious Diseases* 2011, 11:193.
57. Shete AV, Thakar MR, **Tripathy SP**, Raut CG, Chakrabarti S, Paranjape RS. T-cell Epitopes Identified by BALB/c Mice Immunized with Vaccinia Expressing HIV-1 Gag lie within Immunodominant Regions Recognized by HIV-infected Indian Patients. *Journal of Global Infectious Diseases* Jul-Sep 2011; Vol-3 / Issue-3:246-253.
58. Robertson K, Kumwenda J, Supparatpinyo K, Jiang JH, Evans S, Campbell TB, Price RW, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Masih R, Santos B, Silva MT, Kumarasamy N, Walawander A, Nair A, **Tripathy SP**, Kanyama C, Hosseinipour M, Montano S, Rosa AL, Amod F, Sanne I, Firnhaber C, Hakim J, Brouwers P, and the AIDS Clinical Trials Group. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. *J Neurovirol* 2011;17:438–447.
59. Jadhav S, **Tripathy S**, Kulkarni S, Chaturbhuj D, Ghare R, Bhattacharya J, Paranjape R. Genetic conservation in gp36 transmembrane sequences of Indian HIV type 2 isolates. *AIDS Res Hum Retroviruses* 2011;27(12):1337-43.
60. Omer SB; Six week extended dose nevirapine (SWEN) Study Team. Collaborators: Bedri A, Gudetta B, Isehak A, Kumbi S, Mengistu Y, Bhore AV, Bhosale R, Gupte N, Sastry J, Suryavanshi N, **Tripathy S**, Varadhrajan V, Mmiro F, Mubiru M, Musoke P, Nakabiito C, Onyango C, Taylor A, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwierski S. Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. *AIDS* 2011;25(6):767-76.
61. Ghate M, Deshpande S **Tripathy S**, Godbole S, Nene M, Thakar M, Risbud A, Bollinger R and Mehendale M. Mortality in HIV infected individuals in Pune, India. *Indian J of Med Res* 2011;133:414-420.
62. Gupta A, Bhosale R, Kinikar A, Gupte N, Bharadwaj R, Kagal A, Joshi S, Khandekar M, Karmarkar A, Kulkarni V, Sastry J, Mave V, Suryavanshi N, Thakar M, Kulkarni S, **Tripathy S**, Sambarey P, Patil S, Paranjape R, Bollinger RC, Jamkar A; Six Week Extended-Dose Nevirapine (SWEN) India Study Team. Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. *J Infect Dis.* 2011;203(3):358-63.

63. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaldo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team.(+579 collaborators). Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med.*2011;365(6):493-505.
64. Singh HK, Gupte N, Kinikar A, Bharadwaj R, Sastry J, Suryavanshi N, Nayak U, **Tripathy S**, Paranjape R, Jamkar A, Bollinger RC, Gupta A; SWEN India Study Team. High rates of all-cause and gastroenteritis-related hospitalization morbidity and mortality among HIV-exposed Indian infants. *BMC Infect Dis.* 2011;11:193.
65. **Tripathy S**, Anand A, Inamdar V, Manoj MM, Khillare KM, Datye AS, Iyer R, Kanoj DM, Thakar M, Kale V, Pereira M, Risbud AR. Clinical response of newly diagnosed HIV seropositive and seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India. *Indian J Med Res* 2011;133:521-8.
66. Shete AV, Thakar MR, **Tripathy SP**, Raut C, Chakrabarti S, Paranjape RS. T-cell Epitopes Identified by BALB/c Mice Immunized with Vaccinia Expressing HIV-1 Gag lie within immunodominant Regions Recognized by HIV-infected Indian Patients. *J Glob Infect Dis.* 2011;3(3):246-53. PMID:21887056
67. Thorat SR, Chaturbhuj DN, Hingankar NK, Chandrasekhar V, Koppada R, Datkar SR, Srikantiah P, Garg R, Kabra S, Haldar P, Reddy DC, Bachani D, **Tripathy SP**, Paranjape RS. Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India. *AIDS Res Hum Retroviruses.* 2011;27(12):1291-7. PMID:21568760
68. Kumar, A. Kumar, A. M. V. Gupta, D, Kanchar, A. Mohammed, Srinath S, **Tripathy S**, S. Rajasekaran, S. Chan, P-L. Swaminathan, S. Dewan, P. K. Global guidelines for treatment of tuberculosis among persons living with HIV: unresolved issues [Perspectives] *Int J Tube Lung Dis* 2012; 16(5):573-578.
69. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, **Tripathy S**, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Robert T. Schooley RT, Victor De Gruttola VD, James Gita Hakim JG; PEARLS study team of the ACTG. Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings. *PLOS Medicine* 2012;9 (8):e1001290: 1-16.

70. Tripathy S, Pereira M, **Tripathy SP**. HIV testing in India. *Clin Lab Med*. 2012 Jun;32(2):175-91. PMID:22726998
71. Parkin N, de Mendoza C, Schuurman R, Jennings C, Bremer J, Jordan MR, Bertagnolio S; WHO DBS Genotyping Working Group. Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. *Clin Infect Dis* 2012;54 Suppl 4:S273-9.
72. Robertson K, Jiang H, Kumwenda J, Supparatpinyo K, Evans S, Campbell TB, Price R, Tripathy S, Kumarasamy N, La Rosa A, Santos B; 5199 study team, Silva MT, Montano S, Kanyama C, Faesen S, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Allen R, Housseinipour M, Amod F, Sanne I, Hakim J, Walawander A, Nair A; AIDS Clinical Trials Group. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. *Clin Infect Dis*. 2012 Sep;55(6):86876.
73. Hingankar NK, Thorat SR, Deshpande A, Rajasekaran S, Chandrasekar C, Kumar S, Srikantiah P, Chaturbhuj DN, Datkar SR, Deshmukh PS, Kulkarni SS, Sane S, Reddy DC, Garg R, Jordan MR, Kabra S, **Tripathy SP**, Paranjape RS. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. *Clin Infect Dis*. 2012;54 Suppl 4:S348-54. PMID:22544202
74. Chaturbhuj DN, Deshmukh PS, Hingankar NK, Siddhaarth K, Deshpande SN, Sen S, Kabra S, Paranjape RS, **Tripathy SP**. Evaluations of an in-house drug resistance method for HIV-1 drug resistance using ViroSeq TM 2.0 genotyping system as a gold standard. *J Virol Methods*. 2013 Apr;189(1):87-92. PMID:23353551
75. Pandey S, **Tripathy S**, Paranjape R. Molecular Characterization of Unique inter-subtype HIV-1 A1/C recombinant strain circulating in Pune, India. *AIDS Res Hum Retroviruses* 2013 Sep;29(9):1245-53.
76. Ghate M, **Tripathy S**, Gangakhedkar R, Thakar M, Bhattacharya J, Choudhury I, Risbud A, Bembalkar S, Kadam D, Rewari BB, Paranjape R. Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report. *Indian J Med Res* 2013;137:942-9.
77. Padmapriyadarsini C, **Tripathy S**, Sekar L, Bhavani PK, Gaikwad N, Annadurai S, Narendran G, Selvakumar N, Risbud AR, Sheta D, Rajasekaran S, Thomas A, Wares F, Swaminathan S. Evaluation of a diagnostic algorithm for sputum smear-negative pulmonary tuberculosis in HIV-infected adults. *J Acquir Immune Defic Syndr*. 2013;63(3):331-8.

78. Swindells S, Komarow L, **Tripathy S**, Cain KP, MacGregor RR, Achkar JM, Gupta A, Veloso VG, Asmelash A, OmozOarhe AE, Gengiah S, Lalloo U, Allen R, Shiboski C, Andersen J, Qasba SS, Katzenstein DK; AIDS Clinical Trials Group 5253 Study Team. Screening for pulmonary tuberculosis in HIV-1 infected individuals: AIDS Clinical Trials Group Protocol A5253. *Int J Tuberc Lung Dis*. 2013;17(4):532-9.
79. Sharma SK, Mohan A, Chauhan LS, Narain JP, Kumar P, Behera D, Sachdeva KS, Kumar A; Task Force for Involvement of Medical Colleges in Revised National Tuberculosis Control Programme, Agarwal P, Awadh NT, Bansal A, Baruah S, Baruwa P, Balasangameshwara VH, Balasubramanian R, Bhardwaj AK, Bhargav S, Chadha S, Chaddha VK, Chhatwal M, Da Costa AL, Dash DP, Dep J, Dhingra S, Dhooria Harmeet S, Frieden TR, Garg A, Granich R, Gulati V, Gupta D, Gupta D, Gupta KB, Gupta KN, Jaikishan, Janmeja AK, Jawahar MS, Jethani SL, Jindal SK, John KR, Kalra OP, Kalra VP, Kannan AT, Kayshap S, Keshav Chander G, Khushwa SS, Kushwaha RS, Kumar V, Laskar B, Leela Itty Amma KR, Leuva AT, Maitra Malay K, Mesquita AM, Mathew T, Mundade Y, Munje R, Nagpal S, Nagaraja C, Nair S, Narayanan OR, Paramasivan CN, Parmar M, Prasad R, Phukan AC, Prasanna R, Purty A, Ramachandran R, Ramachandran R, Ravindran C, Reddy Raveendra HR, Sahu S, Santosha, Sarin R, Sarkar S, Sarma KC, Saxena P, Sehgal S, Sharath N, Sharma G, Sharma N, Shridhar PK, Shukla RS, Singh O, Singh NT, Singh V, Singla R, Sinha N, Sinha P, Sinha S, Solanki R, Sreenivas A, Srinath S, Subhakar K, Suri JC, Talukdar P, Tonsing J, **Tripathy SP**, Vaidyanathan P, Vashist RP, Venu K. Contribution of medical colleges to tuberculosis control in India under the Revised National Tuberculosis Control Programme (RNTCP): lessons learnt & challenges ahead. *Indian J Med Res*.2013;137(2):283-294. PMID:23563371
80. Antwal M, Gurjar R, Chidrawar S, Pawar J, Gaikwad S, Panchal N, Kale V, ThakarM, Risbud A, **Tripathy S**. Clinical profile of HIV infected patients attending a HIV referral clinic in Pune, India. *Indian J Med Res* 2014;140:271-7. IF **1.661**
81. Patil RT, Rajiv M. Gupta, Sourav Sen, **Tripathy SP**, Devidas N. Chaturbhuj, Nitin K. Hingankar Ramesh S. Paranjape. Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from Pune, India, at the end of 12 months of first line antiretroviral therapy initiation. *ISRN AIDS*.2014;674906. PMID:25006528
82. Kumar M, Sen S, Gupta RK, Chaturbhuj D, **Tripathy SP**, Paranjape RS. Prevalence of drug resistance in human immunodeficiency virus type 1-infected treatment-naive children in Pune, India. *AIDS Res Hum Retroviruses* 2014 Mar;30(3):294-8. PMID:24387706
83. Chaturbhuj DN, Nirmalkar AP, Paranjape RS, **Tripathy SP**. Evaluation of a cost effective in-house method for HIV-1 drug resistance genotyping using plasma samples. *PLoS One*. 2014 Feb 12;9(2):e87441. PMID:24533056

84. Shiboski CH, Chen H, Ghannoum MA, Komarow L, Evans S, Mukherjee PK, Isham N, Katzenstein D, Asmelash A, Omozoarhe AE, Gengiah S, Allen R, **Tripathy S**, Swindells S; Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253. AIDS Clinical Trials Group Network and Oral HIV/AIDS Research Alliance. *Int J Tuberc Lung Dis.* 2014;18(6):682-688.
85. Hingankar NK, Paranjape RS, **Tripathy SP**. Development of subtype specific RealTime PCR based growth competition assay for assessing the replication. *BMC Infectious Diseases* 05/2014; 14(Suppl 3):O1-O1.
86. Shivakoti R, Yang WT, Gupte N, Berendes S, Rosa A, Cardoso SW, Mwelase N, Kanyama C, Pillay S, Samaneka W, Riviere C, Sugandhavesa P, Santos B, Poongulali S, **Tripathy S**, Bollinger RC, Currier JS, Tang AM, Semba RD, Christian P, Campbell TB, Gupta A; Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation. New Work Concept Sheet 319 and The Prospective Evaluation of Antiretrovirals in Resource-Limited Settings Study Team. *Clin Infect Dis.* 2015 Jul 1;61(1):102-10.
87. Shivakoti R, Christian P, Yang WT, Gupte N, Mwelase N, Kanyama C, Pillay S, Samaneka W, Santos B, Poongulali S, **Tripathy S**, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Tang AM, Semba RD, Campbell TB, Gupta A; for the NWCS 319 and PEARLS Study Team. Prevalence and risk factors of micronutrient deficiencies pre- and postantiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. *Clin Nutr.* 2015 Feb 10. **IF 3.94.**
88. Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, **Tripathy S**, Morgado MG, Saravanan S, Balakrishnan P, Reitsma M, Hart S, Mellors JW, Halvas E, Grinsztejn B, Hosseinipour MC, Kumwenda J, La Rosa A, Lalloo UG, Lama JR, Rassool M, Santos BR, Supparatpinyo K, Hakim J, Flanigan T, Kumarasamy N, Campbell TB, Eshleman SH; for the AIDS Clinical Trials Group (ACTG) A5175 Study Team. Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. *Clin Infect Dis.* 2015 May 15;60(10):1541-9. **IF 9.416**
89. Mahajan SD, Gaekwad A, Pawar J, **Tripathy S**, Ghate M, Bhattacharya J, Singh HO, Schwartz SA, Paranjape R, Gangakhedkar R. Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF- α -238 G/A Single Nucleotide Gene Polymorphism. *Curr HIV Res.* 2015;13(2):98-108.
90. Mawar N, Katendra T, Bagul R, Bembalkar S, Vedamurthachar A, **Tripathy S**, Srinivas K, Mandar K, Kumar N, Gupte N and Paranjape RS. Sudarshan Kriya yoga improves quality of life in healthy people living with HIV (PLHIV): results from an open label randomized clinical trial. *Indian J Med Res* 2015;141:90-99.

91. Chakravarty J, Sundar S, Chourasia A, Singh PN, Kurle S, **Tripathy SP**, Chaturbhuj DN, Rai M, Agarwal AK, Mishra RN, Paranjape RS. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. *BMC Infect Dis.*2015; 15:517. PMID: 26572102
92. Mohanty PS, Naaz F, Katara D, Misba L, Kumar D, Dwivedi DK, Tiwari AK, Chauhan DS, Bansal AK, **Tripathy SP**, Katoch K. Viability of *Mycobacterium leprae* in the environment and its role in leprosy dissemination. *Indian J Dermatol Venereol Leprol.* 2016 Jan-Feb;82(1):23-7. PMID: 26728806
93. Ashokkumar M, **Tripathy SP**, Hanna LE. Variability in V1V2 and PNGs in Pediatric HIV-1 Viral Variants Transmitted Through Vertical Route. *AIDS Res Hum Retroviruses.*2016; 32(10-11):942-943. PMID: 27309849
94. Verma R, Balakrishnan L, Sharma K, Khan AA, Advani J, Gowda H, **Tripathy SP**, Suar M, Pandey A, Gandotra S, Prasad TS, Shankar S. A network map of Interleukin-10 signaling pathway. *J Cell Commun Signal.*2016;10(1):61-7. PMID: 26253919
95. Verma R, Pinto SM, Patil AH, Advani J, Subba P, Kumar M, Sharma J, Dey G, avikumar R, Buggi S, Satishchandra P, Sharma K, Suar M, **Tripathy SP**, Chauhan DS, Gowda H, Pandey A, Gandotra S, Prasad TS. Quantitative Proteomic and Phosphoproteomic Analysis of H37Ra and H37Rv Strains of *Mycobacterium tuberculosis*. *J Proteome Res.* 2017;16(4):1632-1645. PMID: 28241730
96. Vidya Vijayan KK, Karthigeyan KP, **Tripathi SP**, Hanna LE. Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections. *Frontiers in Immunology*, 2017;8:580. PMID: 28588579
97. Ashokkumar M, Nesakumar M, Cheedarla N, Vidyavijayan KK, Babu H, **Tripathy SP**, Hanna LE. Molecular Characteristics of the Envelope of Vertically Transmitted HIV-1 Strains from Infants with HIV Infection. *AIDS Research and Human Retroviruses*, 2017;33(8):796-806. PMID: 28401776
98. Padmapriyadarsini C, Saravanan N, Ramalingam B, **Tripathy S**. Malnutrition: Modulator of immune responses in tuberculosis. *Frontiers in Immunology*, 2017;8(Article 1316):1-8. PMID: 29093710
99. Narayanaiah C, Hemalatha B, Anangi B, Muthuramalingam K, Selvachithiram M, Sathyamurthi P, Kailasam N, Varadarajan R, Swaminathan S, **Tripathy SP**, Vaniambadi SK, Vadakkupattu DR, Hanna LE. Evolution of neutralization response in HIV-1 subtype C-infected individuals exhibiting broad cross-clade neutralization of HIV-1 strains. *Frontiers in Immunology*, 2018;9:618:1-16. PMID:29662494

100. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. GBD 2016 Healthcare Access and Quality Collaborators. *Lancet*, 391(10136):2236-2271. PMID: 29893224
101. Ponnann SM, Swaminathan S, Kannan T, K K V, Narayanaiah C, Nesakumar M, Kathirvel S, Goyal R, Singla N, Mukherjee J, Bergin P, T Kopycinski J, Gilmour J, **Tripathy SP**, Hanna LE. Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India. *PLoS One*, 2018;13(8):e0203037. PMID: 30157242
102. Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, **Tripathy SP**, Khaparde SD. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. *BMJ Global Health*, 2018;3(5):e001135. PMID : 30364389
103. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, 2018;392(10159):1684-1735. PMID : 30496102
104. GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, 2018;392(10159):1995-2051. PMID: 30496106
105. GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, 2018;392(10159):2091-2138. PMID: 30496107
106. Sivakumar S, Kumar N, Nair D, Natrajan M, **Tripathy SP**, Peacock SJ, Swaminathan S, Ranganathan UD. Genome Sequencing of Polydrug-, Multidrug-, and extensively drug-resistant *Mycobacterium tuberculosis* strains from south India. *Microbiology Resource Announcements*, 2019; 21;8(12).
107. Dolla CK, Dhanraj B, Malaisamy M, Padma Priyadarshini C, Syeed Hissar S, Natrajan M, Krishnan R, **Tripathy SP**. Burden of pulmonary tuberculosis in modern prison: A cross sectional prevalence survey from South India. *Indian Journal of Tuberculosis*, 2019;66(1):189-192.

108. Advani J, Verma R, Chatterjee O, Pachouri PK, Upadhyay P, Singh R, Yadav J, Naaz F, Ravikumar R, Buggi S, Suar M, Gupta UD, Pandey A, Chauhan DS, **Tripathy SP**, Gowda H, Prasad TSK. Whole genome sequencing of *Mycobacterium tuberculosis* clinical isolates from India reveals genetic heterogeneity and region-specific variations that might affect drug susceptibility. *Frontiers in Microbiology*, 2019;10:309.
109. Cheedarla N, Sundaramurthi JC, Hemalatha B, Anangi B, Nesakumar M, Ashokkumar M, Vidya Vijayan KK, **Tripathy SP**, Swaminathan S, Vaniambadi SK, Ramanathan DV, Hanna LE. Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1. *AIDS Research and Human Retroviruses*, 2019;35(2):169-184.
110. Soundarya JSV, Ranganathan UD, **Tripathy SP**. Current trends in tuberculosis vaccine. *Medical Journal Armed Forces India*, 2019;75(1):18-24.
111. Advani J, Verma R, Chatterjee O, Devasahayam Arokiya Balaya R, Najjar MA, Ravishankara N, Suresh S, Pachori PK, Gupta UD, Pinto SM, Chauhan DS, **Tripathy SP**, Gowda H, Prasad TSK. Rise of Clinical Microbial Proteogenomics: A Multiomics Approach to Nontuberculous Mycobacterium-The Case of Mycobacterium abscessus UC22. *OMICS*, 2019;23(1):1-16.
112. Vidyavijayan KK, Cheedarala N, Babu H, Precilla LK, Sathyamurthi P, Chandrasekaran P, Murugavel KG, Swaminathan S, **Tripathy SP**, Hanna LE. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India. *Frontiers in Immunology*, 2018;9:2841.
113. GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, 392(10159):2091-2138.(NIRT)
114. GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, 2018;392(10159):1995-2051. (NIRT)
115. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1684-1735. (NIRT)
116. Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, **Tripathy SP**, Khaparde SD. Tuberculosis

- preventive treatment: the next chapter of tuberculosis elimination in India. *BMJ Global Health*, 2018;3(5):e001135.
117. GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *Lancet*, 2018;391(10136):2236-2271.(NIRT)
 118. Gopalan N, Santhanakrishnan RK, Palaniappan AN, Menon PA, Lakshman S, Chandrasekaran P, Sivaramakrishnan GN, Reddy D, Kannabiran BP, Agiboth HKK, Krishnamoorthy V, Rathinam S, Chockalingam C, Manoharan T, Ayyamperumal M, Jayanthi N, Satagopan K, Narayanan R, Krishnaraja R, Sathiyavelu S, Kesavamurthy B, Suresh C, Selvachitiram M, Arasan G, Susaimuthu S, Rathinam P, Angamuthu P, Jayabal L, Murali L, Ramachandran R, **Tripathy SP**, Swaminathan S. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial. *JAMA Internal Medicine*, 2018;178(4):485-493.
 119. Ashokkumar M, Aralaguppe SG, **Tripathy SP**, Hanna LE, Neogi U. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses. *Journal of Virology*, 2018; 13;92(9).
 120. Palumbo PJ, Fogel JM, Hudelson SE, Wilson EA, Hart S, Hovind L, Piwowar-Manning E, Wallis C, Papathanasopoulos MA, Morgado MG, Saravanan S, Tripathy S, Eron JJ, Gallant JE, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Pilotto JH, Kumwenda J, Akelo V, Godbole SV, Santos BR, Grinsztejn B, Panchia R, Chariyalertsak S, Makhema J, Badal-Faesen S, Chen YQ, Cohen MS, Eshleman SH. HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. *Journal of Acquired Immune Deficiency Syndrome*, 2018 Apr 15;77(5):484-491.

Accepted:

1. Advani J, Verma R, Chatterjee O, Devasahayam Arokiya Balaya R, Najar MA, Ravishankara N, Suresh S, Pachori PK, Gupta UD, Pinto SM, Chauhan DS, **Tripathy SP**, Gowda H, Prasad TSK. Rise of Clinical Microbial Proteogenomics: A Multiomics Approach to Nontuberculous Mycobacterium-The Case of Mycobacterium abscessus UC22. *OMICS*, 2018 Sep 12.
2. Cheedarla N, Sundaramurthi JC, Hemalatha B, Brahmaiah A, Nesakumar M, Ashokkumar M, Kk VV, **Tripathy SP**, Swaminathan S Dr, Vaniambadi S K, Ramanathan VD, Hanna LE. Mapping of neutralizing antibody epitopes on the envelope of viruses obtained from plasma samples exhibiting broad cross-clade neutralization potential against HIV-1. **AIDS Res Hum Retroviruses**.

Chapters in Books, Publications in Proceedings & non indexed journals:

1. Malaviya AN, Chaudhuri K, Singh YN, **Tripathy S.** (1990) AIDS- facts, problems, solutions. The offsetters, New Delhi (Publ.).
2. **Tripathy S.** Epidemiology of HIV infection in India. Proceedings of the National Conference on HIV/AIDS Medicine held at Pune 23rd - 24th Nov 1996 pg 13-15.
3. **Tripathy S.** Virology of HIV (Review article). Proceedings of the National Conference on HIV/AIDS Medicine held at Pune 23rd - 24th Nov 1996 pg 19-23.
4. Joshi DR, Toshniwal R, **Tripathy SP**, Menon PA, Khatavkar P, Paranjape RS, Mehendale SM, Gadkari DA. Clinical and radiological presentation of tuberculosis in HIV seropositive and HIV seronegative patients in Pune. Proceedings of First National Conference on HIV/AIDS Medicine, Pune 23-24th Nov 1996 pg 35-39.
5. **Tripathy S**, Narain JP. Tuberculosis and Human Immunodeficiency Virus Infection. Chapter 36. Tuberculosis (2001). Sharma SK, Mohan A (eds). Jaypee Bros., Medical Publishers (P) Ltd. New Delhi.
6. Jai Prakash Narain, **Srikanth Prasad Tripathy**, Emauele Pontali. Tuberculosis and HIV Infection. Chapter 6 in the book: Tuberculosis Epidemiology and Control (2002). Jai P Narain. Publication of the World Health Organization, Regional Office for South-east Asia, New Delhi.pg 83-104.
7. **Srikanth P Tripathy.** History of HIV in India. Chapter 2. In the book: AIDS in Asia (2004). Lu Y, Essex M (eds). Kluwer Academic/ Plenum Publishers (New York, Boston, Dordrecht, London, Moscow) Pg 35-45.
8. Sriram P Tripathy, **Srikanth P Tripathy.** Tuberculosis Control, HIV/TB and India (2004). Chapter 19. In the book: AIDS in Asia. Lu Y, Essex M (eds). Kluwer Academic/ Plenum Publishers (New York, Boston, Dordrecht, London, Moscow) Pg 255-267.
9. **Srikanth P Tripathy**, Sriram P Tripathy. Multidrug resistant TB, TB Control and Millenium Development Goals in Asia. In the book: Emerging Infections in Asia (2008). .Lu Y, Essex M and Roberts B (eds) Springer Science+Business Media, LLC. New York (NY) (Publishers) pg 209-231.
10. Sunil K. Arora, R.S. Paranjape, **Srikanth Tripathy**, Ajay Wanchu. Human Immunodeficiency Virus: Biology and Natural History of Infection. In the book: HIV Infection and AIDS. Chapter 66.
11. **Tripathy S**, Piang M, Narain JP. Tuberculosis and Human Immunodeficiency Virus Infection. Chapter 40.
12. Tuberculosis (2nd edition 2009). Sharma SK, Mohan A (eds). Jaypee Bros., Medical Publishers (P) Ltd. New Delhi, Ahmedabad, Bengaluru, Chennai, Hyderabad, Kochi, Kolkata, Lucknow, Mumbai, Nagpur (India), St. Louis (USA).
13. Tripathy, Srikanth P, **Tripathy SP.** 2013. HIV/AIDS Treatment and Control in India and the Millennium Development Goals. In: Yichen Lu, M. Essex and C. Chanyasulkit, eds. 2013. HIV/AIDS Treatment in Resource Poor Countries - Public Health Challenges. New York: Springer. pp.33-44.

14. Chaturbhuji DN, **Tripathy SP**, Paranjape RS, Narain JP. HIV drug resistance in Asia: an emerging problem? Three decades of HIV/AIDS in Asia. Edited by: Narain JP. National Centre for Disease Control, New Delhi, India.